PDL1 In Primary Colorectal Carcinoma and Its Prognostic Impact

Immunohistochemical Expression of PDL1 In Primary Colorectal Carcinoma and Its Prognostic Impact

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05692895

Enrollment

Registered

2023-01-20

Start date

2023-02-28

Completion date

2023-07-31

Last updated

2023-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PDL1- Colorectal Carcinoma

Brief summary

Colorectal cancer (CRC) is a highly heterogenous disease. It the third most commonly diagnosed cancer in the world and the second cause of death among cancer cases mortality. Its incidence is rising all over the world, especially in developing countries . In Egypt it is coming the seventh cancer in incidence according to World Health Organization (WHO, 2020). Although there is much improvement in the diagnosis and treatment, but CRC is still constituting a big impact on human life and health, so researchers are trying to find out new therapeutic targets . Programmed cell death protein 1 (PD-1) is an inhibitory receptor which is expressed on the surface of T lymphocytes during activation. Its role is to control T cell effector activity for various cellular responses as infections, autoimmune reactions, and cancer . Cancer cells develop PD-ligand1 (PD-L1) expression which is a transmembrane molecule belonging to B7 family. Its action is through PD-1/PD-L1 reaction, and causing invasion and metastasis of cancer cells by protecting it from immunosurveillance by inhibiting T cell effector function, leading to carcinogenesis and development of many cancers including colorectal cancer.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 90 Years

Healthy volunteers

Inclusion criteria

1. Both endoscopic and excisional biopsy specimens. 2. All the studied cases include sufficient materials for the immunohistochemical study. 3. Complete clinical data

Exclusion criteria

1. Patients with recurrence of the primary tumor. 2. Patients with a history of preoperative chemotherapy and/or radiotherapy. 3. Insufficient or tiny tissue biopsies

Design outcomes

Primary

Measure	Time frame	Description
Diagnosis and prognosis of colorectal carcinoma	Two or three days after staining tissue sections with PDL1 antibody	Immunohistochemical expression of PDL1 in primary colorectal carcinoma

Contacts

Primary ContactAmira A Abdelnaby, Lecturer

ameraabdelnaby55@gmail.com01002097612

Backup ContactAmira Ahmed Abdelnaby, Lecturer